JP2016513069A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513069A5
JP2016513069A5 JP2015540830A JP2015540830A JP2016513069A5 JP 2016513069 A5 JP2016513069 A5 JP 2016513069A5 JP 2015540830 A JP2015540830 A JP 2015540830A JP 2015540830 A JP2015540830 A JP 2015540830A JP 2016513069 A5 JP2016513069 A5 JP 2016513069A5
Authority
JP
Japan
Prior art keywords
formulation
aqueous
dvd
protein
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015540830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513069A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/068110 external-priority patent/WO2014071212A2/en
Publication of JP2016513069A publication Critical patent/JP2016513069A/ja
Publication of JP2016513069A5 publication Critical patent/JP2016513069A5/ja
Pending legal-status Critical Current

Links

JP2015540830A 2012-11-01 2013-11-01 安定な二重可変ドメイン免疫グロブリンタンパク質製剤 Pending JP2016513069A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261721364P 2012-11-01 2012-11-01
US61/721,364 2012-11-01
US201361794231P 2013-03-15 2013-03-15
US61/794,231 2013-03-15
PCT/US2013/068110 WO2014071212A2 (en) 2012-11-01 2013-11-01 Stable dual variable domain immunoglobulin protein formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019118152A Division JP2019189633A (ja) 2012-11-01 2019-06-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤

Publications (2)

Publication Number Publication Date
JP2016513069A JP2016513069A (ja) 2016-05-12
JP2016513069A5 true JP2016513069A5 (enExample) 2016-12-22

Family

ID=49585619

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015540830A Pending JP2016513069A (ja) 2012-11-01 2013-11-01 安定な二重可変ドメイン免疫グロブリンタンパク質製剤
JP2019118152A Pending JP2019189633A (ja) 2012-11-01 2019-06-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤
JP2020178626A Pending JP2021020943A (ja) 2012-11-01 2020-10-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019118152A Pending JP2019189633A (ja) 2012-11-01 2019-06-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤
JP2020178626A Pending JP2021020943A (ja) 2012-11-01 2020-10-26 安定な二重可変ドメイン免疫グロブリンタンパク質製剤

Country Status (15)

Country Link
US (3) US20140161817A1 (enExample)
EP (2) EP3466973A1 (enExample)
JP (3) JP2016513069A (enExample)
KR (1) KR20150079866A (enExample)
CN (1) CN105431453A (enExample)
AU (3) AU2013337644A1 (enExample)
BR (1) BR112015009924A2 (enExample)
CA (1) CA2889488A1 (enExample)
HK (1) HK1213204A1 (enExample)
IL (2) IL238264A0 (enExample)
MX (2) MX2015005495A (enExample)
RU (2) RU2015120605A (enExample)
SG (2) SG10201802044RA (enExample)
TW (3) TW201422236A (enExample)
WO (1) WO2014071212A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336152B (es) 2009-08-29 2016-01-08 Abbvie Inc Proteinas terapeutico de union a dll4.
EP3072904A1 (en) 2010-03-02 2016-09-28 Abbvie Inc. Therapeutic dll4 binding proteins
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
CA2931978A1 (en) 2013-12-02 2015-06-11 Abbvie Inc. Compositions and methods for treating osteoarthritis
US20150291689A1 (en) 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
WO2015191760A2 (en) 2014-06-10 2015-12-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016118921A1 (en) 2015-01-24 2016-07-28 Abbvie, Inc. Compositions and methods for treating psoriatic arthritis
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
CN108025071B (zh) * 2015-09-17 2022-11-01 斯克利普斯研究院 双重可变结构域免疫缀合物及其用途
EP3397281B1 (en) * 2015-12-29 2020-09-09 Outlook Therapeutics, Inc. Buffered formulations of bevacizumab
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
CN108261544B (zh) 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN108261391B (zh) * 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
EP3658183A1 (en) 2017-07-28 2020-06-03 H. Hoffnabb-La Roche Ag Bispecific antibody formulation
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
EP3774925A1 (en) * 2018-04-13 2021-02-17 Institut national de la santé et de la recherche médicale (INSERM) Fc-engineered anti-human ige antibodies and methods of use
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术(上海)有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113082203B (zh) * 2020-01-09 2023-10-20 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂
EP4147711A4 (en) * 2020-04-20 2024-04-24 Shionogi & Co., Ltd Formulation containing hmgb1 partial peptide
CA3197104A1 (en) * 2020-11-11 2022-05-19 Hq Han Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
EP4251197A4 (en) * 2020-11-25 2024-10-23 Dr. Reddy's Laboratories Ltd. STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MANUFACTURE THEREOF
WO2025231015A1 (en) * 2024-04-30 2025-11-06 Context Therapeutics Inc. Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof
US20250333499A1 (en) * 2024-04-30 2025-10-30 Context Therapeutics Inc. Bispecific antibodies and methods of using the same
CN120346170A (zh) * 2025-03-13 2025-07-22 武汉友芝友生物制药股份有限公司 抗EpCAM和CD3双特异性抗体药物组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
RU2317999C2 (ru) 2000-02-25 2008-02-27 Те Гавернмент Оф Те Юнайтед Стейтс, Эз Репризентед Бай Те Секретари Оф Те Департмент Оф Хелт Энд Хьюман Сервисез SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR0110927A (pt) 2000-05-19 2003-03-11 Scancell Ltd Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
CN101525384A (zh) * 2000-06-29 2009-09-09 艾博特公司 双特异性抗体及其制备方法和用途
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP5646457B2 (ja) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
JP2011523853A (ja) * 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
BRPI0915448A2 (pt) * 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
ES2717883T3 (es) * 2010-03-25 2019-06-26 Ucb Biopharma Sprl Moléculas de DVD-LG estabilizadas con disulfuro
MY161302A (en) * 2010-05-14 2017-04-14 Abbvie Inc IL-1 binding proteins
EP2635694A4 (en) * 2010-11-02 2015-11-11 Abbott Lab VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
AU2011361720B2 (en) * 2010-12-21 2017-04-27 Abbvie Inc. IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use

Similar Documents

Publication Publication Date Title
JP2016513069A5 (enExample)
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
JP2016512050A5 (enExample)
JP2012045397A5 (enExample)
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2014003370A1 (es) Composición acuosa estable de anticuerpos anti-baffr; y dispositivo de suministro de la composición.
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
PL3060229T3 (pl) Stabilne, wodne formulacje przeciwciała
TWD166031S (zh) 口含物
TWD168530S (zh) 容器
JP2015525307A5 (enExample)
TWD167214S (zh) 包裝用容器
JP2016031825A5 (enExample)
JP2015516943A5 (enExample)
JP2013535391A5 (enExample)
JP2013227283A5 (enExample)
CY1123536T1 (el) Τρυγικο αλας του 5-χλωρο-θειοφαινο-2-καρβοξυλικου οξεος [(s)-2-[meθyλo-3-(2-oξo-πυρρολιδιν-1-υλ)-βενζολοσουλφονυλαμινο]-3-(4-μεθυλο-πιπεραζιν-1-υλ)-3-οξο-προπυλ]αμιδιου
JP2012186616A5 (enExample)
JP2016107746A5 (enExample)
CN302028187S (zh) 酒瓶(丰谷酒王15年)
TWD162138S (zh) 眼鏡(二)
CN302314225S (zh) 眼镜(tw14)
CN302314221S (zh) 眼镜(026)
TWD175622S (zh) 可摺疊髮梳
CN302586459S (zh) 燃气灶(7)